199800 Stock Chart & Stats
₩28050.00
₩200.00(0.72%)
―
--
Day’s Range― - ―
52-Week Range₩27,250.00 - ₩139,669.49
Previous CloseN/A
VolumeN/A
Average Volume (3M)28.14K
Market Cap
₩274.11B
Enterprise Value₩316.12B
Total Cash (Recent Filing)₩19.06B
Total Debt (Recent Filing)₩168.41M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4355.53
Shares Outstanding9,774,629
10 Day Avg. Volume23,970
30 Day Avg. Volume28,143
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)11.87
Price to Sales (P/S)507.38
P/FCF Ratio-32.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue growth alongside an approximately 92% gross margin indicates that ToolGen’s gene-editing offerings can generate substantial gross profit from expanding sales. If maintained, this combination provides a platform for reinvestment and eventual operating leverage as the company develops its business.
Low Financial LeverageMinimal debt reduces fixed financing obligations and limits balance-sheet risk while ToolGen funds research and legal activity. Substantial equity provides a stronger capital base than a highly leveraged structure, preserving financial flexibility even though current returns on that capital remain negative.
New Capital For Operations And R&DThe completed capital increase gives ToolGen additional resources to continue operations and pursue its genome-editing strategy over the 2026–2028 period. Funding for R&D and patent-related work could help preserve its technology position and support future licensing opportunities.
Bears Say
Persistent Operating LossesDeeply negative operating and net margins show that revenue growth is not yet translating into a profitable operating model. The reversal from 2024 profit to large 2025 and TTM losses weakens earnings quality and may require continued external funding while development activities continue.
Ongoing Cash BurnSustained negative operating and free cash flow means ToolGen is not currently self-funding its activities, despite modest directional improvement in free cash flow. Continued cash consumption can constrain investment choices and increase reliance on future financing to support research and operations.
Patent Litigation And Dilution RiskLarge legal commitments make protection of ToolGen’s CRISPR patent estate financially important but introduce an extended use of capital with uncertain outcomes. If disputes persist or outcomes are adverse, additional fundraising and dilution could pressure ownership value and force research cutbacks.
ToolGen Incorporated News
199800 FAQ
What was ToolGen Incorporated’s price range in the past 12 months?
ToolGen Incorporated lowest stock price was ₩27250.00 and its highest was ₩139669.49 in the past 12 months.
What is ToolGen Incorporated’s market cap?
ToolGen Incorporated’s market cap is ₩274.11B.
When is ToolGen Incorporated’s upcoming earnings report date?
ToolGen Incorporated’s upcoming earnings report date is Nov 18, 2026 which is in 21 days.
How were ToolGen Incorporated’s earnings last quarter?
ToolGen Incorporated released its earnings results on Aug 14, 2026. The company reported -₩741.674 earnings per share for the quarter.
Is ToolGen Incorporated overvalued?
According to Wall Street analysts ToolGen Incorporated’s price is currently Undervalued.
Does ToolGen Incorporated pay dividends?
ToolGen Incorporated does not currently pay dividends.
What is ToolGen Incorporated’s EPS estimate?
ToolGen Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ToolGen Incorporated have?
ToolGen Incorporated has 9,774,629 shares outstanding.
What happened to ToolGen Incorporated’s price movement after its last earnings report?
ToolGen Incorporated reported an EPS of -₩741.674 in its last earnings report. Following the earnings report the stock price went down -1.399%.
Which hedge fund is a major shareholder of ToolGen Incorporated?
Currently, no hedge funds are holding shares in KR:199800
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ToolGen Incorporated
ToolGen Inc. is a biotechnology firm dedicated to the research and development of cutting-edge genome editing technologies. The company supplies a variety of ready-to-use reagents for gene engineering experiments, including purified gRNA/Cas9, standard gRNA/Cas9, and recombinant Cas9 protein. Beyond its product offerings, ToolGen also provides specialized services such as the creation of genome-edited cell lines, genetically modified mice/rats, and altered plants, in addition to performing surrogate reporter synthesis and in-del analysis.
Technical Analysis
ORIENTBIO, Inc.
―
Pharmicell Co., Ltd
―
GeneOne Life Science, Inc.
―
Bioneer Corporation
―
Genomictree, Inc.
―